Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3131131 | 0.90 | AKR1B1 (0.61) | HRH1LMNAAKR1B1TBXA2RADRA1D | |
| Hydrochloric Acid SCHEMBL3139244 | 0.89 | KCNH2 (0.46) | HRH1LMNASETD7KCNH2 | |
| SCHEMBL3138427 | 0.86 | KCNH2 (0.46) | HRH1SETD7KCNH2 | |
| SCHEMBL3132968 | 0.84 | KCNH2 (0.43) | HRH1LMNASETD7KCNH2 | |
| SCHEMBL3132978 | 0.84 | KCNH2 (0.43) | HRH1LMNASETD7KCNH2 | |
| SCHEMBL3137250 | 0.84 | SETD7 (0.45) | HRH1SETD7KCNH2 | |
| SCHEMBL3034913 | 0.84 | CYP2D6 (0.48) | HRH1LMNAAKR1B1TBXA2RADRA1D | |
| SCHEMBL3138558 | 0.84 | ALDH1A1 (0.46) | LMNASETD7KCNH2 | |
| Hydrochloric Acid SCHEMBL3036924 | 0.83 | CYP2D6 (0.48) | HRH1LMNAAKR1B1TBXA2RADRA1D | |
| Hydrochloric Acid SCHEMBL3137251 | 0.83 | SETD7 (0.51) | HRH1LMNATBXA2RADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067777-B1 | OXEPIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8222419-B2 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100004456-A1 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2067777-A1 | OXEPIN DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004456-A1 | Oxepin derivative | HRH4, HRH3, HCRTR2 | HRH1 7/4885LMNA 4838/4885AKR1B1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.